Precision Brain Health Research Act of 2025
Summary
S. 800 (Precision Brain Health Research Act of 2025) expands the VA's biomarker research mandate but authorizes zero new funding. The bill is reported out of committee and awaiting floor action. Labcorp ($LH at $262.63) and Quest Diagnostics ($DGX at $194.98) show no legislative catalyst in their recent price trends—both are down ~0.5-1.6% over the last 30 days. No near-term market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S. 800 expands VA biomarker research but authorizes ZERO new funding—it is a mandate bill, not a spending bill.
- 2.Labcorp ($LH) and Quest Diagnostics ($DGX) show no price reaction to this legislation; both are down ~0.5-1.6% in the last 30 days.
- 3.Any revenue for diagnostic service providers requires a separate appropriations bill—likely not before FY2028 at the earliest.
- 4.The bill is awaiting Senate floor action; current legislative momentum is low with only 3 cosponsors.
Market Implications
Labcorp ($LH at $262.63) and Quest Diagnostics ($DGX at $194.98) are not moving on this bill. The 30-day price declines of -1.57% and -0.51% respectively indicate no legislative catalyst. This is correct pricing behavior—the bill authorizes zero dollars. Investors should not expect any contract revenue from this legislation until FY2028 appropriations are passed. The April 2026 executive order on psychedelic therapies is a separate policy track and should not be conflated with this bill's biomarker research mandate.
Full Analysis
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Expanded biomarker research mandate at VA for low-level blast exposure, dementia, and other brain conditions; requires identification and validation of biomarkers; authorizes zero new funding.
Who must act
Department of Veterans Affairs (VA) and Department of Defense (DoD) under a new data-sharing partnership.
What happens
VA must expand its biomarker research program scope but has no new appropriations to fund external contracts; any future diagnostic service contracts would require separate appropriations legislation.
Stock impact
Labcorp could be a future vendor for biomarker testing services if VA appropriates funds, but with no funding authorized and the bill awaiting floor action, there is zero near-term revenue visibility for Labcorp's diagnostic services segment.
What the bill does
Same expanded biomarker research mandate at VA; potential future contract opportunities for diagnostic testing services, but no funding mechanism.
Who must act
Department of Veterans Affairs (VA).
What happens
VA research expansion creates a potential procurement need for biomarker testing, but without appropriations it is a legislative authorization only—no contract dollars obligated.
Stock impact
Quest Diagnostics could compete for VA testing contracts, but with no funding authorized and the bill stalled at committee report stage, there is no current or near-term revenue impact for Quest's government diagnostic services business.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
SUPPORT for Patients and Communities Reauthorization Act of 2025
ASAP Act
CHOICE for Veterans Act of 2025
Reducing Hereditary Cancer Act
Access to Breast Cancer Diagnosis Act of 2025
Thyroid Disease CARE Act of 2025
Supporting Healthy Moms and Babies Act
Increasing Access to Lung Cancer Screening Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Imposing Sanctions on Those Responsible for Repression in Cuba and for Threats to United States National Security and Foreign Policy
This Executive Order expands the existing national emergency against the Government of Cuba by imposing broad secondary sanctions and asset freezes on foreign persons operating in key sectors of the Cuban economy (energy, defense, metals/mining, financial services, security). It authorizes the Treasury and State Departments to block property and deny entry to individuals and entities involved in repression, corruption, or support for the Cuban government, and empowers Treasury to sanction foreign financial institutions that facilitate transactions for designated persons. The order effectively tightens the U.S. embargo by targeting third-country companies and banks that do business with Cuba.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Presidential Determination Pursuant to Section 303 of the Defense Production Act of 1950, as Amended, on Domestic Petroleum Production, Refining, and Logistics Capacity
The President, under the authority of Section 303 of the Defense Production Act of 1950, has determined that domestic petroleum production, refining, and logistics capacity are essential for national defense. This action authorizes the Secretary of Energy to make purchases, commitments, and provide financial support to expand these capabilities, waiving certain DPA requirements to expedite the process.